Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project-Reference-Cited by-同舟云学术

Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project

Published:2010-06 Issue:6-7 Volume:103 Page:404-410
ISSN:1875-2136
Container-title:Archives of Cardiovascular Diseases
language:en
Short-container-title:Archives of Cardiovascular Diseases

Author:

Donal Erwan,Lund Lars,Linde Cecilia,Daubert Jean-Claude

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference63 articles.

1. Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction;Donal;Eur J Heart Fail,2009

2. Heart failure;Jessup;N Engl J Med,2003

3. Heart failure with preserved systolic function: a diagnostic algorithm for a pragmatic definition;Juilliere;Arch Mal Coeur Vaiss,2006

4. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology;Paulus;Eur Heart J,2007

5. Understanding “diastolic” heart failure;Redfield;N Engl J Med,2004

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conduction system pacing on track to replace CRT? Review of current evidence and prospects of conduction system pacing;Frontiers in Cardiovascular Medicine;2023-08-15

2. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction;European Journal of Heart Failure;2017-03-21

3. Management of the Patient with Heart Failure with Preserved Ejection Fraction;Heart Failure;2017

4. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction;JACC: Heart Failure;2016-06

5. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial;European Journal of Heart Failure;2016-05-15